Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

59.45 +0.02 (+0.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results

August 12, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year...

Via StockStory

Is BioMarin Pharmaceutical Gaining or Losing Market Support? ↗

August 12, 2025

Via Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 ↗

August 05, 2025

BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth.

Via Benzinga

BioMarin (BMRN) Q2 Revenue Jumps 16% ↗

August 04, 2025

Via The Motley Fool

Topics Economy

BioMarin (BMRN) Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars

August 04, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year...

Via StockStory

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Exceeds Q2 2025 Earnings Expectations, Shares Climb After Hours ↗

August 04, 2025

BioMarin Pharmaceutical beats Q2 2025 estimates with $825.4M revenue, EPS of $1.44, and raises full-year guidance. Stock surges 4.6% post-earnings.

Via Chartmill

BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect

August 02, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings this Monday after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence Economy World Trade

What's Next: Biomarin Pharmaceutical's Earnings Preview ↗

August 01, 2025

Via Benzinga

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics ↗

July 29, 2025

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact.

Via Benzinga

1 Mid-Cap Stock Worth Investigating and 2 We Turn Down

July 25, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

What Does the Market Think About BioMarin Pharmaceutical? ↗

July 23, 2025

Via Benzinga

Demystifying BioMarin Pharmaceutical: Insights From 4 Analyst Reviews ↗

July 22, 2025

Via Benzinga

1 Cash-Producing Stock to Consider Right Now and 2 We Ignore

July 18, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗

July 17, 2025

BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) shows strong profitability, solid financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.

Via Chartmill

Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money ↗

July 16, 2025

Three magnificent businesses with well-defined catalysts can deliver triple-digit returns amid a historically pricey stock market.

Via The Motley Fool

Topics Economy Stocks

Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks

July 14, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.

Via StockStory

Topics Artificial Intelligence

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong Fundamentals ↗

June 26, 2025

BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

2 Profitable Stocks for Long-Term Investors and 1 to Be Wary Of

June 26, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

2 Reasons to Watch BMRN and 1 to Stay Cautious

June 23, 2025

Over the last six months, BioMarin Pharmaceutical’s shares have sunk to $55.23, producing a disappointing 16.7% loss while the S&P 500 was flat. This might have investors contemplating their next...

Via StockStory

Topics Stocks

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗

June 12, 2025

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.

Via Benzinga

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 ↗

June 05, 2025

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Via The Motley Fool

Topics Stocks

1 Mid-Cap Stock with Exciting Potential and 2 to Avoid

June 05, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗

June 04, 2025

BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

Top movers in Friday's after hours session ↗

May 23, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)

May 19, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens ↗

May 16, 2025

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Via Stocktwits

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover ↗

May 16, 2025

Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.

Via Investor's Business Daily

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

May 16, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.